About Wockhardt
Wockhardt is a company based in Mumbai (India) founded in 1967 by Habil Khorakiwala. It operates as a HealthTech and Direct-to-Consumer (D2C). The company has 3,410 employees as of March 31, 2024. Wockhardt has completed 1 acquisition, including Pinewood. Wockhardt offers products and services including Zaynich, Heparin Sodium Flushing Solution, and Heparin Sodium 5000 I.U./ml.
- Headquarter Mumbai, India
- Employees 3410 as on 31 Mar, 2024
- Founders Habil Khorakiwala
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Wockhardt Limited
-
Annual Revenue
$341.2 M (USD)4.52as on Mar 31, 2025
-
Net Profit
-$5.5 M (USD)89.85as on Mar 31, 2025
-
EBITDA
$35.12 M (USD)104.08as on Mar 31, 2025
-
Latest Funding Round
$118.48 M (USD), Post-IPO
Nov 12, 2024
-
Investors
Société Générale
& 10 more
-
Employee Count
3410
as on Mar 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Wockhardt
Wockhardt is a publicly listed company on the NSE with ticker symbol WOCKPHARMA in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Wockhardt
Wockhardt offers a comprehensive portfolio of products and services, including Zaynich, Heparin Sodium Flushing Solution, and Heparin Sodium 5000 I.U./ml.
Antibiotic developed to combat multidrug-resistant infections globally.
Solution used for maintaining catheter patency in patients.
Anticoagulant administered to prevent blood clot formation.
People of Wockhardt
Unlock access to complete
Funding Insights of Wockhardt
Investors in Wockhardt
Wockhardt has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Société Générale, HSBC and HDFC Mutual Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Mirae Asset is engaged in mutual fund and asset management services.
|
Locked | Locked | Locked | |
|
Investment fund managing portfolios in sectors like finance, logistics, and engineering in India.
|
Locked | Locked | Locked | |
|
Real estate funds are managed through multiple investment strategies.
|
Locked | Locked | Locked |
Investor details for Wockhardt
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Wockhardt
Wockhardt has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Pinewood.
Investment portfolio details for Wockhardt
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Manufacturer of renal care drugs
|
Locked | Locked | 1976 | Locked |
Complete acquisition details for Wockhardt
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Wockhardt
Detailed financials for Wockhardt
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Wockhardt Comparisons
Peer comparison for Wockhardt
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Wockhardt
Detailed competitors of Wockhardt
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Wockhardt
Complete news archive for Wockhardt
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Wockhardt
Wockhardt was founded in 1967 and raised its 1st funding round 57 years after it was founded.
Wockhardt is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Habil Khorakiwala is the current CEO of Wockhardt. They have also founded this company.
As of Mar 31, 2024, the latest employee count at Wockhardt is 3,410.
Annual revenue of Wockhardt is $341.2M as on Mar 31, 2025.
Wockhardt is recognized as a research-based global enterprise focused on pharmaceuticals, biotechnology, and healthcare services. Operations are conducted across multiple sectors including branded pharmaceuticals, active pharmaceutical ingredients (APIs), and biologics. Manufacturing and RD facilities are established in India, USA, UK, and UAE, supporting a presence in over 30 countries. Solutions are provided for antimicrobial resistance through novel antibiotics like Zaynich, currently in clinical trials. Additionally, super-specialty hospitals and social initiatives are managed under associated entities to enhance healthcare access and quality of life.
Wockhardt offers Zaynich, Heparin Sodium Flushing Solution, and Heparin Sodium 5000 I.U./ml.
Yes, Wockhardt is publicly traded on NSE under the ticker symbol WOCKPHARMA.
Wockhardt has made 1 acquisition, including Pinewood.
Wockhardt has 11 investors. Key investors include Société Générale, HSBC, HDFC Mutual Fund, Mirae Asset, and ICICI Prudential Asset Management Company.
The ticker symbol of Wockhardt is WOCKPHARMA on NSE.